Zobrazeno 1 - 10
of 54
pro vyhledávání: '"Tak Takvorian"'
Autor:
Jeremy S. Abramson, Elizabeth Bengston, Robert Redd, Jeffrey A. Barnes, Tak Takvorian, Lubomir Sokol, Frederick Lansigan, Philippe Armand, Bijal Shah, Eric Jacobsen, Rosalba Martignetti, Elyce Turba, Sara Metzler, Victoria Patterson, Ann S. LaCasce, Celeste M. Bello
Publikováno v:
Blood Advances. 7:1130-1136
ABVD (Adriamycin, bleomycin, vinblastine, dacarbazine) with or without radiation has been the standard treatment for limited-stage Hodgkin lymphoma (HL) but carries risks of bleomycin lung injury and radiation toxicity. Brentuximab vedotin (BV) is ap
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::40e6d7122bf785841b263f83eb4c1cfc
https://doi.org/10.1182/bloodadvances.2022008420
https://doi.org/10.1182/bloodadvances.2022008420
Autor:
Jennifer R. Brown, Donna Neuberg, Lillian Werner, Robert P. Hasserjian, Philippe Armand, Eric D. Jacobsen, Ann S. LaCasce, David C. Fisher, Kathleen M. Leahy, Karen K. Ballen, Ephraim P. Hochberg, Tak Takvorian, Eyal C. Attar, Philip C. Amrein
Purpose: Chronic lymphocytic leukemia (CLL) cells treated with dasatinib in vitro undergo apoptosis via inhibition of Lyn kinase. Thus, in this study we tested the activity of dasatinib in patients with relapsed CLL.Experimental Design: Patients were
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aadc7708d1fdfb43f7b4346bc6f08f7b
https://doi.org/10.1158/1078-0432.c.6518805.v1
https://doi.org/10.1158/1078-0432.c.6518805.v1
Autor:
Jennifer R. Brown, Donna Neuberg, Lillian Werner, Robert P. Hasserjian, Philippe Armand, Eric D. Jacobsen, Ann S. LaCasce, David C. Fisher, Kathleen M. Leahy, Karen K. Ballen, Ephraim P. Hochberg, Tak Takvorian, Eyal C. Attar, Philip C. Amrein
Supplementary Figure S1; Supplementary Tables S1-S2.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ec58e26d8591bea031bc9e1301124c0
https://doi.org/10.1158/1078-0432.22441947.v1
https://doi.org/10.1158/1078-0432.22441947.v1
Autor:
Colette Owens, Allison P. Jacob, Jade Ruiters, Sidney Sechio, Audrey Hamilton, Clare Grieve, Puja Chadha, Mikhail Roshal, Tak Takvorian, Daneal Portman, Anthony R. Mato, Krista J Scorsune, Jason Carter, Ahmet Dogan, Lauren Ramos, Ai Ni, Natascha Nolet, Juliana M.L. Biondo, Jane Huang, Ephraim P. Hochberg, Anita Kumar, Stephanie Hughes, Morgan Choma, M. Lia Palomba, Rosalba Martignetti, Ariela Noy, Jeffrey A. Barnes, Meghan C. Thompson, P. Connor Johnson, Jeremy S. Abramson, Connie Lee Batlevi, Julia M Lynch, Qun Wu, Chaya Friedman, Erel Joffe, Joanna Mi, Brianne McGree, Elizabeth Simkins, Venkatraman E. Seshan, Matthew J. Matasar, Kelsey Flaherty, Omar Abdel-Wahab, Lindsey E. Roeker, Andrew D. Zelenetz, Jacob D. Soumerai, Neena Mahajan
Publikováno v:
The Lancet Haematology. 8:e879-e890
Summary Background We hypothesised that combining zanubrutinib with obinutuzumab and venetoclax (BOVen) as an initial therapy for chronic lymphocytic leukaemia and small lymphocytic lymphoma would lead to high rates of undetectable minimal residual d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cdf7327afd36fee111882d955455bfdf
https://doi.org/10.1016/s2352-3026(21)00307-0
https://doi.org/10.1016/s2352-3026(21)00307-0
Autor:
Jeremy S, Abramson, Elizabeth, Bengtson, Robert A, Redd, Jeffrey A, Barnes, Tak, Takvorian, Lubomir, Sokol, Frederick, Lansigan, Philippe, Armand, Bijal D, Shah, Eric D, Jacobsen, Rosalba, Martignetti, Elyce, Turba, Sara, Metzler, Victoria, Patterson, Ann S, LaCasce, Celeste M, Bello
Publikováno v:
Blood advances.
ABVD with or without radiation has been standard treatment for limited stage HL but carries risks of bleomycin-lung injury and radiation toxicity. Brentuximab vedotin (BV) is approved with AVD as frontline therapy for stage III-IV HL, but carries inc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::0412a61511b9631841b5118e7f7ec29f
https://pubmed.ncbi.nlm.nih.gov/36053786
https://pubmed.ncbi.nlm.nih.gov/36053786
Autor:
E. M. Bengston, Lubomir Sokol, C. M. Bello, S. R. Metzler, B. Shah, Jeremy S. Abramson, Tak Takvorian, Jeffrey A. Barnes, E. Turba, Robert A. Redd, Rosalba Martignetti, Frederick Lansigan, P. Armand, Victoria Patterson, Ann S. LaCasce, Eric N. Jacobsen
Publikováno v:
Hematological Oncology. 39
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::37ff4e15e122a5abebca58afd6ef0c66
https://doi.org/10.1002/hon.110_2880
https://doi.org/10.1002/hon.110_2880
Autor:
David C. Fisher, Eric D. Jacobsen, Donna Neuberg, Jeffrey A. Barnes, Robert A. Redd, Tak Takvorian, Jeremy S. Abramson, Ephraim P. Hochberg
Publikováno v:
Hematological Oncology. 36:633-637
This is a phase II study of panobinostat, an oral pan-HDAC inhibitor, combined with rituximab in patients with relapsed diffuse large B cell lymphoma. Panobinostat was administered orally 3 times a week every other week on a 28-day cycle. Rituximab w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6add1d3534993476768925a1b3fd23fe
https://doi.org/10.1002/hon.2515
https://doi.org/10.1002/hon.2515
Autor:
Jeffrey A. Barnes, Jenny Wu, Anita A Kumar, Krista J Scorsune, Allison P. Jacob, Jade Ruiters, Connie Lee Batlevi, Rosalba Martignetti, Chaya Friedman, Venkatraman E. Seshan, Daneal Portman, Audrey Hamilton, Ai Ni, Anthony R. Mato, Morgan Choma, Meghan C. Thompson, Clare Grieve, Jane Huang, Elizabeth Simkins, Ahmet Dogan, Tak Takvorian, Jason Carter, Brianne McGree, Colette Owens, Julia M Lynch, Ariela Noy, Puja Chadha, Sidney Sechio, Mikhail Roshal, Erel Joffe, Joanna Mi, M. Lia Palomba, Kelsey Flaherty, Lindsey E. Roeker, Natascha Nolet, Andrew D. Zelenetz, Stephanie Hughes, P. Connor Johnson, Matthew J. Matasar, Omar Abdel-Wahab, Jacob D. Soumerai, Juliana M.L. Biondo, Neena Mahajan, Ephraim P. Hochberg, Jeremy S. Abramson
Publikováno v:
Blood. 138:3753-3753
Background: Venetoclax (Ven; BH3 mimetic) and Obinutuzumab (O; CD20 antibody) is an approved, fixed-duration regimen (one year) that induces undetectable minimum residual disease (uMRD) and durable remissions in treatment naïve patients (pts) with c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d7655bd9ce25ab3178eacf658c568de1
https://doi.org/10.1182/blood-2021-150961
https://doi.org/10.1182/blood-2021-150961
Autor:
Frank Kuhr, Barbara Pro, Jane N. Winter, Jeffrey A. Barnes, Lik Wee Lee, Juehua Gao, Valerie Nelson, Shuo Ma, Leo I. Gordon, Adam M. Petrich, Deborah M. Stephens, Jason B. Kaplan, Reem Karmali, Tak Takvorian, Jeremy S. Abramson, Ephraim P. Hochberg
Publikováno v:
Blood. 138:3530-3530
BACKGROUND: Maintenance rituximab in MCL has improved survival and supports the exploration of maintenance with novel targeted agents. Ibrutinib is a BTK inhibitor approved for relapsed/refractory MCL. We report the final analysis of safety and effic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0b5afaf42e441a42e6629fce860d4740
https://doi.org/10.1182/blood-2021-144707
https://doi.org/10.1182/blood-2021-144707
Autor:
Anthony R. Mato, Erel Joffe, Jeffrey A. Barnes, Tak Takvorian, Jeremy S. Abramson, Ariela Noy, Audrey Hamilton, Lauren Ramos, Ahmet Dogan, Kelsey Flaherty, Ephraim P. Hochberg, Lindsey E. Roeker, Andrew D. Zelenetz, Jason Carter, Matthew J. Matasar, Connie Lee Batlevi, Colette Owens, Omar Abdel-Wahab, Maria Lia Palomba, Jacob D. Soumerai
Publikováno v:
Journal of Clinical Oncology. 38:8006-8006
8006 Background: Venetoclax (Ven)-Obinutuzumab (O) is approved for chronic lymphocytic leukemia (CLL) achieving frequent undetectable minimum residual disease (uMRD; Fischer NEJM 2019). Ven-Ibrutinib is synergistic with frequent uMRD but with grade >
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::96782990d9a9ba1ebabfee3bbaf32e78
https://doi.org/10.1200/jco.2020.38.15_suppl.8006
https://doi.org/10.1200/jco.2020.38.15_suppl.8006